RESULTS

BACKGROUND

- We thank staff involved in JAB-21822-1002 and JAB-21822-1007 studies.
- COI: In relation to this presentation, Andrea Wang-Gillam is an employee of Jacobio Pharmaceuticals, Inc., and J. Li declares no conflicts of interest.
- We thank the patients participating in the studies.

REFERENCE

We present the data of JAB-21822 monotherapy (NCT05009329) and in combination with cetuximab (NCT05194995) for advanced CRC patients.

- Glecirasib (JAB-21822; Jacobio, China) is a novel, highly selective, orally bioavailable, covalent KRASG12C inhibitor
- KRASG12C mutations act as oncogenic drivers. In China, these mutations occur in approximately 2.5% of colorectal cancer (CRC) cases.

Efficacy results demonstrate promising clinical activity in both JAB-21822 monotherapy and JAB-21822 plus cetuximab in patients with KRASG12C mutant advanced CRC.

EXHIBITION

- JAB-21822 yielded ORR 33.3% (11/33), DCR 90.9% (30/33) and mPFS of 6.9 months.
- JAB-21822 + Cetuximab in Advanced CRC Study Design

Table 1. Baseline Characteristics

Table 2: Objective Response Rate per RECIST 1.1

Table 3: Treatment-Related Adverse Events (TRAE) with frequency > 10% in patients

PRELIMINARY RESULTS

- JAB-21822 yielded ORR 33.3% (11/33), DCR 90.9% (30/33) and mPFS of 6.9 months.
- JAB-21822 + cetuximab resulted in ORR 62.8% (27/43) and DCR 93% (40/43).
- COO and mPFS were reached for combination study.

Efficacy results demonstrate promising clinical activity in both JAB-21822 monotherapy and JAB-21822 plus cetuximab in patients with KRASG12C mutant advanced CRC.

CONCLUSION

- We thank the patients participating in the studies.
- We thank all the investigators at each study site.
- We thank staff involved in JAB-21822-1002 and JAB-21822-1007 studies.
- Contact: miao.ju@jacobio.com
- COI: In relation to this presentation, Andrea Wang-Gillam is an employee of Jacobio Pharmaceuticals, Inc., and J. Li declares no conflicts of interest.

REFERENCES


ACKNOWLEDGEMENTS

- We thank the patients participating in the studies.
- We thank all the investigators at each study site.
- We thank staff involved in JAB-21822-1002 and JAB-21822-1007 studies.

- COI: In relation to this presentation, Andrea Wang-Gillam is an employee of Jacobio Pharmaceuticals, Inc., and J. Li declares no conflicts of interest.

REFERENCES


ACKNOWLEDGEMENTS

- We thank the patients participating in the studies.
- We thank all the investigators at each study site.
- We thank staff involved in JAB-21822-1002 and JAB-21822-1007 studies.

- COI: In relation to this presentation, Andrea Wang-Gillam is an employee of Jacobio Pharmaceuticals, Inc., and J. Li declares no conflicts of interest.